The present invention is directed to a carbamazepine-cyclodextrin inclusioncomplex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrininclusion complex is prepared by the admixture of a modified cyclodextrin andcarbamazepine in a physiologically acceptable fluid. Modified cyclodextrinsinclude 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins.More particularly, the sulfoalkyl cyclodextrins are those described and disclosedin U.S. Patent Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluidincludes sterile isotonic water, Ringer's lactate, D5W (5 % dextrose inwater), physiological saline, and similar fluids suitable for parenteral administration.
